Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Free Report) has been given an average rating of “Hold” by the sixteen analysts that are covering the stock, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers […]
Headlands Technologies LLC bought a new stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,182 shares of the company’s stock, valued at approximately $374,000. Other institutional investors and hedge funds have also made […]
Headlands Technologies LLC bought a new position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund bought 1,182 shares of the company’s stock, valued at approximately $374,000. A number of other institutional investors have also recently bought and sold shares of the business. State of […]
Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.